The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women

European Journal of Cancer

Volumn 39, Issue 7, 2003, Pages 861-869

  Robertson, J F R ^a   Blamey, R W ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

'Zoladex'; Adjuvant; Breast cancer; Castration; GnRH agonist; Goserelin; Ovarian suppression; Tamoxifen

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN AGONIST; GOSERELIN; METHOTREXATE; TAMOXIFEN;

ADVANCED CANCER; ALOPECIA; AMENORRHEA; ANOREXIA; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLIMACTERIUM; CLINICAL TRIAL; CYTOTOXICITY; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; EARLY CANCER; FATIGUE; HISTOLOGY; HOT FLUSH; HUMAN; INFECTION; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; OVARIECTOMY; PREMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STOMATITIS; VAGINAL DRYNESS;

EID: 0037403245     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00810-9     Document Type: Review

References (53)

1. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma. suggestions for a new method of treatment with illustrative cases Lancet. 2:1896;104-107.
2. Furr B.J. Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogue, 'Zoladex'. Horm. Res. 32(Suppl. 1):1989;86-92.
3. Veronesi U., Pizzocaro G., Rossi A. Oophorectomy for advanced carcinoma of the breast. Surg. Gynecol. Obstet. 141:1975;569-570.
4. Ingle J.N., Krook J.E., Green S.J.et al. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J. Clin. Oncol. 4:1986;178-185.
5. Oriana S., Bohm S., Baeli A., Scavone G., Riboldi G., Torri A. Clinical response and survival according to estrogen receptor levels after bilateral ovariectomy in advanced breast cancer. Eur. J. Surg. Oncol. 15:1989;39-42.
6. Conte C.C., Nemoto T., Rosner D., Dao T.L. Therapeutic oophorectomy in metastatic breast cancer. Cancer. 64:1989;150-153.
7. Klijn J.G., de Jong F.H. Treatment with a leuteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer. Lancet. 1:1982;1213-1216.
8. Williams M.R., Walker K.J., Turkes A., Blamey R.W., Nicholson R.I. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br. J. Cancer. 53:1986;629-636.
9. Jonat W. Zoladex™ versus CMF adjuvant therapy in pre/perimenopausal breast cancer. tolerability and amenorrhoea comparisons Proceedings of ASCO. 19:2000;87a. [abstr 333].
10. Kaufmann M., Jonat W., Kleeberg U.et al. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J. Clin. Oncol. 7:1989;1113-1119.
11. Williamson K., Robertson J.F., Ellis I.O., Elston C.W., Nicholson R.I., Blamey R.W. Effect of LHRH agonist, Zoladex, on ovarian histology. Br. J. Surg. 75:1988;595-596.
12. Robertson J.F., Walker K.J., Nicholson R.I., Blamey R.W. Combined endocrine effects of LHRH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer. Br. J. Surgery. 76:1989;1262-1265.
13. Cohen I., Tepper R., Figer A., Flex D., Shapira J., Beyth Y. Successful co-treatment with LHRH-agonist for ovarian over-stimulation and cystic formation in premenopausal tamoxifen exposure. Breast Cancer Res. Treat. 55:1999;119-125.
14. Nicholson R.I., Walker K.J., McClelland R.A., Dixon A., Robertson J.F., Blamey R.W. Zoladex plus tamoxifen versus Zoladex alone in pre- and peri-menopausal metastatic breast cancer. J. Steroid Biochem. Mol. Biol. 37:1990;989-995.
15. Blamey R.W., Jonat W., Kaufmann M., Bianco A.R., Namer M. Goserelin depot in the treatment of premenopausal advanced breast cancer. Eur. J. Cancer. 28A:1992;810-814.
16. Blamey R.W., Jonat W., Kaufmann M., Bianco A.R., Namer M. Survival data relating to the use of goserelin depot in the treatment of premenopausal advanced breast cancer. Eur. J. Cancer. 29A:1993;1498.
17. Taylor C.W., Green S., Dalton W.S.et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer. an intergroup study J. Clin. Oncol. 16:1998;994-999.
18. Harvey H.A., Lipton A., Max D.T., Pearlman H.G., Diaz-Perches R., de la Garza J. Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer. J. Clin. Oncol. 3:1985;1068-1072.
19. Dowsett M., Mehta A., Mansi J., Smith I.E. A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients. Br. J. Cancer. 62:1990;834-837.
20. Dowsett M., Jacobs S., Aherne J., Smith I.E. Clinical and endocrine effects of leuprorelin acetate in pre- and postmenopausal patients with advanced breast cancer. Clin. Ther. 14(Suppl. A):1992;97-103.
21. Untch M. Primary endocrine therapy as pre- and perimenopausal metastatic breast carcinoma with leuprorelin acetate depot. German Leuprorelin Study Group. Zentralbb Gynakol. 120:1998;284-292.
22. Lissoni P., Barni S., Crispino S., Cattaneo G., Tancini G. Endocrine and clinical effects of an LHRH analogue in pretreated advanced breast cancer. Tumori. 74:1988;303-308.
23. Klijn J.G., de Jong F.H., Lamberts S.W., Blankenstein M.A. LHRH-agonist treatment in clinical and experimental human breast cancer. J. Steroid Biochem. 23:1985;867-873.
24. Klijn J.G., Beex L.V., Mauriac L.et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer. a randomized study J. Natl. Cancer Inst. 92:2000;903-911.
25. Klijn J.G. Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments. Med. Oncol. Tumor Pharmacother. 1:1984;123-128.
26. Celio L., Martinetti A., Ferrari L.et al. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor. a comparative endocrine study Anticancer Res. 19:1999;2261-2268.
27. Garcia-Giralt E., Beuzeboc P., Dieras V.et al. Phase II trial of decapeptyl (D-TRP-6), a potent lutenizing hormone-releasing hormone analogue in untreated advanced breast cancer. Am. J. Clin. Oncol. 19:1996;455-458.
28. Neskovic-Konstantinovic Z.B., Vuletic L.B., Nikolic-Stanojevic L.I.et al. Therapeutic and endocrine effects of Decapeptyl, synthetic LH-RH agonistic analogue in premenopausal women with metastatic breast cancer. A pilot phase II study. Oncology. 51:1994;95-101.
29. Robertson J.F., Nicholson R.I., Walker K.J., Blamey R.W. Zoladex in advanced breast cancer. Horm. Res. 32(Suppl 1):1989;206-208.
30. Boccardo F., Rubagotti A., Perrotta A.et al. Ovarian ablation versus goserelin with or without tamoxifen in pre-/perimenopausal patients with advanced breast cancer. results of a multicentric Italian study Ann. Oncol. 5:1994;337-342.
31. Jonat W., Kaufmann M., Blamey R.W.et al. A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur. J. Cancer. 31A:1995;137-142.
32. Klijn J.G., Blamey R.W., Boccardo F., Tominaga T., Duchateau L., Sylvester R. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer. a meta-analysis of four randomized trials J. Clin. Oncol. 19:2001;343-353.
33. Dowsett M., Doody D., Miall S., Howes A., English J., Coombes R.C. Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer. Breast Cancer Res. Treat. 56:1999;25-34.
34. Stein R.C., Dowsett M., Hedley A., Gazet J.C., Ford H.T., Coombes R.C. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br. J. Cancer. 62:1990;679-683.
35. Cheung K.L., Forward D., Jackson L., Robertson J.F. The combined use of goserelin and anastrozole as second-line endocrine therapy in premenopausal women with advanced breast cancer - a study of its clinical and endocrine effects. Eur. J. Cancer. 37(Suppl. 5):2001;8. [abstr O-22].
36. Early Breast Cancer Trialists' Collaborative Group Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet. 348:1996;1189-1196.
37. Kaufmann M. Zoladex™ (goserelin) vs. CMF as adjuvant therapy in pre/perimenopausal node-positive early breast cancer. Preliminary efficacy results from the ZEBRA study. Breast. 10(Suppl. 1):2001;S30. [abstr P53].
38. Wallwiener D., Possinger K., Bondar G.et al. Leuprorelin acetate vs. CMF in the adjuvant treatment of premenopausal women with ER/PR-positive, node-positive breast cancer: interim results of the TABLE study. Proc ASCO. 20:2001;34a. [abstr 132].
39. Jakesz R, Hausmaninger H, Samonigg H, et al. on behalf of the Austrian Breast & Colorectal Cancer Study Group (ABCSG). Complete endocrine blockade with tamoxifen and goserelin is superior to CMF in the adjuvant treatment of premenopausal, lymph node-positive and-negative patients with hormone-responsive breast cancer. Breast 2001, 10(Suppl. 1), S10 [abstr S26].
40. Boccardo F., Rubagotti A., Amoroso D.et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients. results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial J. Clin. Oncol. 18:2000;2718-2727.
41. Roche H.H., Kerbrat P., Bonneterre J.et al. Complete hormonal blockade versus chemotherapy in premenopausal early-stage breast cancer patients (Pts) with positive hormone-receptor (HR+) and 1-3 node-positive (N+) tumor. results of the FASG 06 Trial Proc ASCO. 19:2000;72a. [abstr 279].
42. Boccardo F., Rubagotti A., Amoroso M.et al. CMF vs tamoxifen (TAM) plus ovarian suppression (OS) as adjuvant treatment of ER-positive (ER+) pre/perimenopausal breast cancer (BCA) patients (Pts). Breast. 10(Suppl. 1):2001;S32. [abstr P62].
43. Baum M, Houghton J, Odling-Smee W, et al. on behalf of the ZIPP Group. Adjuvant Zoladex in premenopausal patients with early breast cancer: results from the ZIPP trial. Breast 2001, 10(Suppl. 1), S32-S33 [abstr P64].
44. Baum M., Houghton J., Sawyer W.et al. Management of premenopausal women with early breast cancer. Is there a role for goserelin? Proc. ASCO. 20:2001;27a. [abstr 103].
45. Davidson N., O'Neill A., Vukov C.K.et al. Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer. an Eastern Cooperative Oncology Group Phase III intergroup trial (E5188, INT-0101) Breast. 8:1999;232-233. [abstr 069].
46. Castiglione-Gertsch M., Gelber R.D., O'Neill A., Coates A.S., Goldhirsch A. Systemic adjuvant treatment for premenopausal node-negative breast cancer. Eur. J. Cancer. 36:2000;549-550.
47. Castiglione-Gertsch M., O'Neill A., Gelber R.D.et al. Is the addition of adjuvant chemotherapy always necessary in node negative (N-) pre/perimenopausal breast cancer patients (pts) who receive goserelin? first results of the IBCSG trial VIII Proc ASCO. 21:2002;38a. [abstr 149].
48. De Matteis A., Montedoro D., Nuzzo F.et al. Hormonotherapy with goserelin depot after adjuvant chemotherapy in premenopausal women with early breast cancer. Is there any benefit? Ann. Oncol. 9(Suppl. 4):1998;11. [abstr 52].
49. Bines J., Oleske D.M., Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 14:1996;1718-1729.
50. Jakesz R., Hausmaninger H., Samonigg H.et al. Comparison of adjuvant therapy with tamoxifen and goserelin vs. CMF in premenopausal stage I and II hormone-responsive breast cancer patients: four year results of Austrian Breast Cancer Study Group (ABCSG) Trial 5. Proceedings of ASCO. 18:1999;67a. [abstr 250].
51. Pagani O., O'Neill A., Castiglione M.et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement. results of the International Breast Cancer Study Group (IBCSG) Trial VI Eur. J. Cancer. 34:1998;632-640.
52. Del Mastro L., Venturini M., Sertoli M.R., Rosso R. Amenorrhoea induced by adjuvant chemotherapy in early breast cancer patients. prognostic role and clinical implications Breast Cancer Res. Treat. 43:1997;183-190.
53. Blamey R.W. The design and clinical use of the NottinghamPrognostic Index in breast cancer. Breast. 22:1996;574-577.